ANAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AnaptysBio Inc (ANAB) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has a bullish technical setup, strong analyst support with raised price targets, and a positive long-term growth outlook. Despite insider selling and a drop in net income, the company's revenue growth and gross margin stability indicate potential for long-term gains.
The technical indicators for ANAB are bullish. The MACD is positive and expanding, the RSI is neutral but leaning towards overbought, and the moving averages are aligned in a bullish order (SMA_5 > SMA_20 > SMA_200). Current price levels are above the pivot point, and resistance levels are near $55.01 and $57.76, suggesting potential for upward movement.
Analysts have raised price targets significantly, with Barclays increasing to $78 and UBS upgrading to Buy with a $70 target.
Positive Phase I data for ANB033 and strong expectations for Jemperli royalties.
Revenue growth of 154.26% YoY in Q3 2025, indicating strong operational performance.
Insider selling has increased by 189.75% over the last month.
Net income and EPS have dropped significantly YoY, which may concern some investors.
No recent news or congress trading data to provide additional confidence.
In Q3 2025, AnaptysBio reported revenue growth of 154.26% YoY, reaching $76.32 million. However, net income dropped by 146% YoY to $15.11 million, and EPS fell by 145.61% YoY to $0.52. Gross margin remains strong at 100%, indicating efficient cost management.
Analyst sentiment is highly positive, with recent upgrades and raised price targets. Barclays raised its target to $78, UBS upgraded to Buy with a $70 target, and Guggenheim raised its target to $140. Analysts cite confidence in ANB033, Jemperli royalties, and the biotech sector's recovery as key drivers.
